DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+42.82%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$417M
AUM Growth
+$417M
(+30%)
Cap. Flow
-$14.8M
Cap. Flow
% of AUM
-3.54%
Top 10 Holdings %
Top 10 Hldgs %
49.63%
Holding
82
New
7
Increased
14
Reduced
24
Closed
6
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$6.14M |
| 2 |
Biohaven
BHVN
|
$5.73M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$5.31M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
$3.28M |
| 5 |
Galapagos
GLPG
|
$2.85M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$12.8M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$7.23M |
| 3 |
Cytokinetics
CYTK
|
$6.64M |
| 4 |
AUTL
Autolus Therapeutics
AUTL
|
$4.75M |
| 5 |
Nurix Therapeutics
NRIX
|
$4.38M |
Sector Composition
| 1 | Healthcare | 85.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Adicet Bio
ACET
$60.8M
| – | – |
-797,054
| Closed | -$1.09M |
|
77
Mersana Therapeutics
MRSN
$34.8M
| – | – |
-29,362
| Closed | -$932K |
|
|
78
Nurix Therapeutics
NRIX
$723M
| – | – |
-556,695
| Closed | -$4.38M |
|
79
NextCure
NXTC
$13.3M
| – | – |
-13,849
| Closed | -$214K |
|
|
THRD
80
DELISTED
Third Harmonic Bio
THRD
| – | – |
-300,000
| Closed | -$1.92M |
|
|
CERE
81
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| – | – |
-62,200
| Closed | -$1.36M |
|